Literature DB >> 22271412

Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells.

Zhi-Gang Chang1, Jun-Min Wei, Chang-Fu Qin, Kun Hao, Xiao-Dong Tian, Kun Xie, Xue-Hai Xie, Yin-Mo Yang.   

Abstract

BACKGROUND: Aberrant expression of epidermal growth factor receptor (EGFR) has been detected in pancreatic cancer; however, the mechanisms of EGFR in inducing pancreatic cancer development have not been adequately elucidated. The objective of this study was to determine the role of EGFR in mediating epithelial-mesenchymal transition (EMT) in pancreatic cancer cells.
METHODS: Pancreatic cancer cell line PANC-1 was transfected with small interfering RNA of EGFR by use of a lentiviral expression vector to establish an EGFR-knockdown cell line (si-PANC-1). PANC-1 cells transfected with lentiviral vector expressing negative control sequence were used as negative control (NC-PANC-1). Scratch assay and transwell study were used to analyze cell migration and invasion. Real-time PCR and Western blotting were used to detect the expression of EMT markers E-cadherin, N-cadherin, vimentin, and fibronectin and transcription factors snail, slug, twist1, and sip1 in PANC-1, NC-PANC-1, and si-PANC-1 cells. Immunofluorescent staining with these antibodies and confocal microscopy were used to observe their cellular location and morphologic changes.
RESULTS: After RNA interference of EGFR, the migration and invasion ability of si-PANC-1 cells decreased significantly. The expression of epithelial phenotype marker E-cadherin increased and the expression of mesenchymal phenotype markers N-cadherin, vimentin, and fibronectin decreased, indicating reversion of EMT. We also observed intracellular translocation of E-cadherin. Expression of transcription factors snail and slug in si-PANC-1 cells decreased significantly.
CONCLUSION: Suppression of EGFR expression can significantly inhibit EMT of pancreatic cancer PANC-1 cells. The mechanism may be related with the down-regulation of the expression of transcription factors snail and slug.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271412     DOI: 10.1007/s10620-012-2036-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

Review 1.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 2.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

3.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

Review 4.  Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.

Authors:  John Marshall
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

5.  E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.

Authors:  Xiaolan Qian; Tatiana Karpova; Allan M Sheppard; James McNally; Douglas R Lowy
Journal:  EMBO J       Date:  2004-04-01       Impact factor: 11.598

6.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 7.  Pancreatic cancer stem cells and EMT in drug resistance and metastasis.

Authors:  F H Sarkar; Y Li; Z Wang; D Kong
Journal:  Minerva Chir       Date:  2009-10       Impact factor: 1.000

8.  Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma.

Authors:  Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Andrzej Kemona; Jolanta Czyzewska
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

9.  Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer.

Authors:  Min Zhang; Xin Zhang; Chun-Xue Bai; Xian-Rang Song; Jie Chen; Lei Gao; Jie Hu; Qun-Ying Hong; Malcolm J West; Ming Q Wei
Journal:  Genet Vaccines Ther       Date:  2005-06-30

Review 10.  Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.

Authors:  Carla E Cano; Yoshiharu Motoo; Juan L Iovanna
Journal:  ScientificWorldJournal       Date:  2010-10-01
View more
  13 in total

1.  Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.

Authors:  Woo Hyun Paik; Ji Kon Ryu; Kyoung-Sin Jeong; Jin Myung Park; Byeong Jun Song; Sang Hyub Lee; Yong-Tae Kim; Yong Bum Yoon
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer.

Authors:  Ding Jie; Zhang Zhongmin; Liao Guoqing; Liu Sheng; Zhang Yi; Wen Jing; Zeng Liang
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

3.  The influence of matrix degradation and functionality on cell survival and morphogenesis in PEG-based hydrogels.

Authors:  Asad Raza; Chien-Chi Lin
Journal:  Macromol Biosci       Date:  2013-06-17       Impact factor: 4.979

4.  The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.

Authors:  Zaklina Kovacevic; Sharleen V Menezes; Sumit Sahni; Danuta S Kalinowski; Dong-Hun Bae; Darius J R Lane; Des R Richardson
Journal:  J Biol Chem       Date:  2015-11-03       Impact factor: 5.157

5.  Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling.

Authors:  Shadan Ali; Aamir Ahmad; Amro Aboukameel; Alia Ahmed; Bin Bao; Sanjeev Banerjee; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2014-05-16       Impact factor: 8.679

6.  EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.

Authors:  Maria J Serrano; Francisco G Ortega; Maria J Alvarez-Cubero; Rosa Nadal; Pedro Sanchez-Rovira; Marta Salido; María Rodríguez; Jose L García-Puche; Miguel Delgado-Rodriguez; Francisco Solé; Maria A García; Macarena Perán; Rafael Rosell; Juan A Marchal; Jose A Lorente
Journal:  Oncotarget       Date:  2014-09-15

7.  Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.

Authors:  Leah K O'Shea; Samar Abdulkhalek; Stephanie Allison; Ronald J Neufeld; Myron R Szewczuk
Journal:  Onco Targets Ther       Date:  2014-01-16       Impact factor: 4.147

8.  MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.

Authors:  Xingchen Zhou; Yuan Hu; Lan Dai; Yunfei Wang; Jinhua Zhou; WenWen Wang; Wen Di; Lihua Qiu
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

9.  Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma.

Authors:  Samar Abdulkhalek; Olivia D Geen; Lacey Brodhagen; Fiona Haxho; Farah Alghamdi; Stephanie Allison; Duncan J Simmons; Leah K O'Shea; Ronald J Neufeld; Myron R Szewczuk
Journal:  Clin Transl Med       Date:  2014-09-23

Review 10.  Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis.

Authors:  Fiona Haxho; Ronald J Neufeld; Myron R Szewczuk
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.